AR040709A1 - Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion - Google Patents

Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion

Info

Publication number
AR040709A1
AR040709A1 AR20030102702A ARP030102702A AR040709A1 AR 040709 A1 AR040709 A1 AR 040709A1 AR 20030102702 A AR20030102702 A AR 20030102702A AR P030102702 A ARP030102702 A AR P030102702A AR 040709 A1 AR040709 A1 AR 040709A1
Authority
AR
Argentina
Prior art keywords
formulation
lamotrigine
release
same
lamotrigin
Prior art date
Application number
AR20030102702A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217493A external-priority patent/GB0217493D0/en
Priority claimed from GB0217492A external-priority patent/GB0217492D0/en
Priority claimed from GB0313801A external-priority patent/GB0313801D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR040709A1 publication Critical patent/AR040709A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulación de lamotrigina o de uno de sus derivados farmacéuticamente aceptables la cual es una formulación de liberación prolongada. Sustancialmente toda la lamotrigina o uno de sus derivados farmacéuticamente aceptables se libera de la formulación 2 a 20 horas después de la administración al paciente. La formulación de liberación prolongada tiene un perfil de disolución in vitro en el que 40 a 65% de la lamotrigina se disuelve en 3 a 8 horas. Preferentemente la liberación de la lamotrigina se produce en al menos dos fases presentes en la formulación, en las que la velocidad de liberación de la primera fase es diferente a la velocidad de liberación de la segunda fase. Uso de lamotrigina para preparar la formulación de liberación prolongada para tratar trastornos del CNS. De la misma manera se reduce la frecuencia de al menos un efecto secundario asociado a la administración de lamotrigina y se logra una concentración en suero que, tras administrar a un paciente la formulación de lamotrigina de liberación prolongada se produce una Cmax que es alrededor de 30% menor que la de un comprimido de liberación instantánea que contenga la misma cantidad de almotrigina.
AR20030102702A 2002-07-29 2003-07-28 Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion AR040709A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0217493A GB0217493D0 (en) 2002-07-29 2002-07-29 Novel methods of treatment
GB0217492A GB0217492D0 (en) 2002-07-29 2002-07-29 Novel method of treatment
GB0313801A GB0313801D0 (en) 2003-06-13 2003-06-13 Novel methods of treatment

Publications (1)

Publication Number Publication Date
AR040709A1 true AR040709A1 (es) 2005-04-13

Family

ID=31499035

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102702A AR040709A1 (es) 2002-07-29 2003-07-28 Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion

Country Status (29)

Country Link
US (1) US20050032799A1 (es)
EP (1) EP1524981B1 (es)
JP (2) JP4744142B2 (es)
KR (1) KR100882707B1 (es)
CN (1) CN100363007C (es)
AR (1) AR040709A1 (es)
AT (1) ATE424827T1 (es)
AU (1) AU2003260336C1 (es)
BR (1) BRPI0313148B8 (es)
CA (1) CA2493301A1 (es)
CO (1) CO5680405A2 (es)
CY (1) CY1109119T1 (es)
DE (1) DE60326590D1 (es)
DK (1) DK1524981T3 (es)
ES (1) ES2323268T3 (es)
HK (1) HK1077003A1 (es)
IL (1) IL166424A (es)
IS (1) IS2681B (es)
MA (1) MA27509A1 (es)
MX (1) MXPA05001243A (es)
MY (1) MY141049A (es)
NO (1) NO334221B1 (es)
NZ (1) NZ537885A (es)
PL (1) PL213565B1 (es)
PT (1) PT1524981E (es)
RU (1) RU2325163C2 (es)
SI (1) SI1524981T1 (es)
TW (1) TWI342213B (es)
WO (1) WO2004012741A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
KR101406456B1 (ko) * 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
WO2008109343A1 (en) * 2007-03-01 2008-09-12 Memory Pharmaceuticals Corporation Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith with (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
US20090196924A1 (en) * 2008-02-04 2009-08-06 Pramod Kharwade Controlled-release lamotrigine formulations
CN102170879B (zh) * 2008-07-18 2014-03-05 威朗国际制药公司 调控释放制剂及其应用方法
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2011086568A1 (en) * 2010-01-13 2011-07-21 Accutest Research Laboratories (I) Pvt. Ltd Controlled release composition for lamotrigine
JP2014504633A (ja) * 2011-02-03 2014-02-24 ルピン・リミテッド 経口投与用放出制御医薬組成物
WO2014159275A1 (en) * 2013-03-14 2014-10-02 PharmTak, Inc. Controlled-release pharmaceutical compositions comprising lamotrigine and methods of producing same
CN103920134A (zh) * 2014-05-08 2014-07-16 崔韡 一种治疗儿童眩晕的缓释片及其制备方法
RU2624229C2 (ru) * 2015-12-21 2017-07-03 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки клозапина с замедленным высвобождением и способ их получения
RU2613192C1 (ru) * 2016-02-18 2017-03-15 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки клозапина с пролонгированным высвобождением
BR112019016118A2 (pt) * 2017-02-03 2020-07-14 Jubilant Generics Limited forma farmacêutica de dosagem de suspensão oral de lamotrigina
IL272834B1 (en) 2017-08-24 2024-04-01 Adamas Pharma Llc Compositions of amantadine, their preparation, and methods of use
KR20200077555A (ko) * 2017-10-27 2020-06-30 창 궁 메모리얼 하스피털, 린커우 항-간질제 라모트리진에 의해 야기된 피부의 약물 이상 반응의 위험 평가 방법, 이를 위한 검출 시약 및 이의 용도
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
CN114948868B (zh) * 2021-04-16 2023-04-14 上海奥科达医药科技股份有限公司 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
JPH0667828B2 (ja) * 1985-10-09 1994-08-31 日研化学株式会社 バルプロ酸ナトリウムの持続性顆粒製剤
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
EP0542364B1 (en) * 1991-11-13 1996-01-24 Glaxo Canada Inc. Controlled release device
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
ES2241055T3 (es) * 1996-08-23 2005-10-16 Endo Pharmaceuticals Inc Composicion que contiene un anticonvulsionante para tratar el dolor neuropatico.
GB9625795D0 (en) * 1996-12-12 1997-01-29 Smithkline Beecham Plc Novel treatment
US6046716A (en) * 1996-12-19 2000-04-04 Colorado Microdisplay, Inc. Display system having electrode modulation to alter a state of an electro-optic layer
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
EP1126827A2 (en) * 1998-11-02 2001-08-29 Alza Corporation Controlled delivery of active agents
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0024517D0 (en) * 2000-10-06 2000-11-22 Glaxo Group Ltd Use of medicaments
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine

Also Published As

Publication number Publication date
IS2681B (is) 2010-09-15
JP2011057683A (ja) 2011-03-24
MXPA05001243A (es) 2005-06-08
CN1681509A (zh) 2005-10-12
IS7707A (is) 2005-02-23
TW200418484A (en) 2004-10-01
RU2005105353A (ru) 2005-10-27
WO2004012741A1 (en) 2004-02-12
DK1524981T3 (da) 2009-06-22
IL166424A0 (en) 2006-01-15
MA27509A1 (fr) 2005-09-01
JP2005538113A (ja) 2005-12-15
NO20050948L (no) 2005-02-22
NZ537885A (en) 2007-11-30
CO5680405A2 (es) 2006-09-29
PL374982A1 (en) 2005-11-14
EP1524981B1 (en) 2009-03-11
CA2493301A1 (en) 2004-02-12
KR100882707B1 (ko) 2009-02-06
NO334221B1 (no) 2014-01-13
PT1524981E (pt) 2009-06-17
ES2323268T3 (es) 2009-07-10
DE60326590D1 (de) 2009-04-23
RU2325163C2 (ru) 2008-05-27
EP1524981A1 (en) 2005-04-27
BR0313148A (pt) 2005-07-12
AU2003260336C1 (en) 2008-05-29
IL166424A (en) 2010-12-30
PL213565B1 (pl) 2013-03-29
ATE424827T1 (de) 2009-03-15
CN100363007C (zh) 2008-01-23
JP4744142B2 (ja) 2011-08-10
US20050032799A1 (en) 2005-02-10
BRPI0313148B1 (pt) 2019-08-20
HK1077003A1 (en) 2006-02-03
CY1109119T1 (el) 2014-07-02
KR20050026054A (ko) 2005-03-14
MY141049A (en) 2010-02-25
BRPI0313148B8 (pt) 2021-05-25
AU2003260336A1 (en) 2004-02-23
TWI342213B (en) 2011-05-21
SI1524981T1 (sl) 2009-08-31

Similar Documents

Publication Publication Date Title
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
PT1239849E (pt) Formulacoes farmaceuticas que compreendem resveratrol e a sua utilizacao
AR040682A1 (es) Forma de dosificacion una vez al dia de pramipexol
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
TW200603787A (en) Topical preparations containing ambroxol
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
NO20073403L (no) Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1
HUP0202671A2 (hu) Ketotifen optikailag aktív izomerei és aktív metabolitjai
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
NO20080244L (no) Doseringsstyring for prasugrel
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
MXPA06007510A (es) Composiciones de farmaco y formas de dosis novedosas de topiramato.
PT1150704E (pt) Melagatran para o tratamento da inflamacao
AR047726A1 (es) Metodos y reactivos para el tratamiento de trastornos inflamatorios
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
AR026631A1 (es) ''3-4-dihidroquinazolinas 5,6-disustituidas''
SE0102887D0 (sv) New formulation

Legal Events

Date Code Title Description
FC Refusal